This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NextGen's (NXGN) Shares Rise on Potential Acquisition Rumors
by Zacks Equity Research
NextGen (NXGN) and a private equity firm, Thomas Bravo, are in advanced stages of discussion related to the acquisition of the former by the latter.
Reasons to Add Stryker (SYK) Stock to Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
Veeva (VEEV) Rises on Robust Earnings: More Room to Grow?
by Zacks Equity Research
Veeva (VEEV) reports better-than-expected earnings and revenues for the second quarter. The raised earnings outlook for fiscal 2024 reflects optimism. Will the uptrend in shares continue?
Cooper Companies (COO) Q3 Earnings In Line, '23 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) third-quarter fiscal 2023 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.
Patterson Companies (PDCO) Q1 Earnings In Line, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) first-quarter fiscal 2024 results reflect robust improvement in Dental Equipment sales, value-added services and Animal Health segment.
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Align Technology (ALGN) Down 9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Earnings Estimates Rising for Align Technology (ALGN): Will It Gain?
by Zacks Equity Research
Align Technology (ALGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Align Technology (ALGN) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?
Here's How Much a $1000 Investment in Align Technology Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Align (ALGN) Rides on Growing Invisalign Sales, New Alliances
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by Invisalign portfolio expansion and raised guidance.
Quest Diagnostics (DGX) Base Volume Aids Amid Low COVID Tests
by Zacks Equity Research
Quest Diagnostics (DGX) continues to witness growth momentum in the cardiometabolic, endocrinology, infectious disease and carrier and prenatal genetic screening services.
Thermo Fisher (TMO) Business Hurt by Low COVID Sales, FX Woe
by Zacks Equity Research
Thermo Fisher (TMO) is witnessing headwinds in the government and academic end markets.
Bruker (BRKR) Set to Acquire PhenomeX in an All-Cash Deal
by Zacks Equity Research
Bruker (BRKR) initiates its entry into since-cell biology research solutions with the acquisition of PhenomeX.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.
Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results benefit from the Pharmaceutical segment's solid performance.
Prescribing Profits: 3 Stocks to Ride the Healthcare Relative Strength
by Ethan Feller
Over the last month, Healthcare has been the second strongest sector in the market
Align Technology (ALGN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Align Technology (ALGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and Align Technology (ALGN) have performed compared to their sector so far this year.
Stock Market News for Jul 27, 2023
by Zacks Equity Research
U.S. stocks ended mixed on Wednesday, with the S&P 500 and the Nasdaq ending slightly lower, as major indexes made a failed attempt to bounce back after the Fed hiked interest rates yet again.
Align Technology (ALGN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 9.90% and 1.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q2 Earnings Due on Jul 26: DGX, TMO and More
by Urmimala Biswas
MedTech companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how DGX, TMO, EW and ALGN fare this time.
West Pharmaceutical Services (WST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.